[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05653310":3,"trial-entities:NCT05653310":83,"trial-summary:NCT05653310":87},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":24,"primary_purpose":25,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":41,"secondary_outcomes":45,"sex":46,"minimum_age":47,"maximum_age":48,"healthy_volunteers":15,"eligibility_criteria":49,"std_ages":59,"locations":62,"central_contacts":72,"overall_officials":73,"references":78,"see_also_links":79},"NCT05653310","21-012527","Tradipitant for Functional Dyspepsia","Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia","ENROLLING_BY_INVITATION","2027-03","2026-07","2026-07-16","2023-02-09","Xiao Jing (Iris) Wang","OTHER",false,"To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.",null,[19],"Functional Dyspepsia",[21,22,23],"tradipitant","NK-1 antagonist","neurokinin 1 receptor","INTERVENTIONAL","BASIC_SCIENCE",[27],"PHASE2",{"count":29,"type":30},60,"ESTIMATED",[32,37],{"type":33,"name":34,"description":35,"armGroupLabels":36},"DRUG","Tradipitant","Tradipitant Capsule",[34],{"type":33,"name":38,"description":39,"armGroupLabels":40},"Placebo","Placebo Capsule",[38],[42],{"measure":43,"timeFrame":44},"Accommodation gastric volumes measured by single photon emission computed tomography (SPECT)","4 Weeks",[],"ALL","18 Years","70 Years",{"inclusion":50,"exclusion":54,"raw_text":58},[51,52,53],"Able to provide written consent","Body Mass Index (BMI) of 18-35 kg\u002Fm2","Absence of other diseases which could interfere with interpretation of study results",[55,56,57],"Current H. pylori infection","Pregnancy or nursing","Recent history of Alcohol Use Disorder or Substance Use Disorder","Inclusion Criteria:\n\n* Able to provide written consent\n* Body Mass Index (BMI) of 18-35 kg\u002Fm2\n* Absence of other diseases which could interfere with interpretation of study results\n\nExclusion Criteria:\n\n* Current H. pylori infection\n* Pregnancy or nursing\n* Recent history of Alcohol Use Disorder or Substance Use Disorder",[60,61],"ADULT","OLDER_ADULT",[63],{"facility":64,"city":65,"state":66,"zip":67,"country":68,"geoPoint":69},"Mayo Clinic in Minnesota","Rochester","Minnesota","55905","United States",{"lat":70,"lon":71},44.02163,-92.4699,[],[74],{"name":75,"affiliation":76,"role":77},"Xiao Jing (Iris) Wang, MD","Mayo Clinic","PRINCIPAL_INVESTIGATOR",[],[80],{"label":81,"url":82},"Mayo Clinic Clinical Trials","https:\u002F\u002Fwww.mayo.edu\u002Fresearch\u002Fclinical-trials",{"nct_id":4,"conditions":84,"biomarkers":86},[85],"Nonulcer dyspepsia",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]